Otsuka ICU Medical LLC announced plans for a $500 million expansion through a new facility and upgrades to its existing facility in Austin, with the goal of improving the long-term supply of IV solutions and supporting new IV products, according to a news release.
What’s happening
Otsuka ICU Medical will expand its existing 700,000-square-foot manufacturing site in Austin with a new 500,000-square-foot facility. The project is meant to help strengthen the supply chain of IV solutions and also bolster the transition to non-DEHP IV solutions containers.
According to Otsuka ICU Medical, natural disasters and infrastructure restraints have created IV supply-chain disruptions in the North American market.
Some context
The expansion is the first major milestone part of the joint venture by ICU Medical Inc. and Otsuka Pharmaceutical Factory Inc., which began in 2025. ICU Medical, which is headquartered in California, specializes in the development, manufacturing and sale of medical devices. Otsuka Pharmaceutical Factory, which is based out of Japan, is a global IV solutions manufacturing subsidiary of Otsuka Holdings Co.
In late 2024, the two entities announced the creation of a joint venture to provide global IV solutions manufacturing networks and bring additional supply chains to North America.
In recent years, states have begun proposing legislation to ban the use of IV bags or medical devices made with DEHP, or di(2-ethylhexyl) phthalate. According to Breast Cancer Prevention Partners, the man-made chemical is used to make IV bags soft and flexible, and studies have shown it can be associated with an increased risk of cancer.
Since 2024, California and North Carolina have both passed laws banning the chemical’s use in medical devices.
What they’re saying
"This expansion reflects our commitment to long-term growth in a clinically essential market," Yoshifumi Fujimoto, CEO of Otsuka ICU Medical LLC, said in the news release. "By strengthening our US manufacturing footprint, expanding non-DEHP capabilities, and introducing innovation, we are enhancing supply reliability for North American customers while positioning ourselves to better support future regulatory and legislative requirements."
